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Abstract
Mice homozygous for either the gld or Ipr mutation develop autoimmune diseases and progressive
lymphadenopathy. The Ipr mutation Is characterized by the absence of functional Fas, whereas gld
mice exhibit an Inactive FasL due to a point mutation proximal to the extracellular C-terminus. The
structural repercussions of this amino acid substitution remain unknown. Here we report that FasL
is expressed at similar levels on the surface of activated T lymphocytes from gld and wild-type
mice. Using a polyclonal anti-FasL antibody, indistinguishable amounts of a 40 kDa protein are
detected In both gld and wild-type splenocytes. The molecular model of FasL, based on the known
structure of TNF-a, predicts that the Phe->Leu gld mutation is located at the protomer interface
which is close to the FasR interaction site. We conclude that the gld mutation allows normal FasL
biosynthesis, surface expression and oligomerlzatlon, but Induces structural alterations to the Fas
binding region leading to the phenotyplc changes observed.
Introduction
FasL is a member of the type II membrane protein superfamily
consisting of TNF-a and -p" (lymphotoxin-a), lymphotoxin-p,
CD27L, CD30L, CD40L and 4-1BB (1). Despite the diversity
of the biological activities elicited by these ligands, most of
them are known to induce cellular differentiation or proliferation
with two exceptions. FasL and, under some circumstances,
TNF are responsible for rapid induction of apoptosis of
receptor-bearing cells (2,3).
The importance of a functional Fas-Fas ligand (FasL)
system is illustrated by the phenotype of Ipr (lymphoprolifera-
tion)and gld (generalized disease) mutant mice. MLR mice
homozygous for Ipr or gld develop a progressive autoimmune
disorder, resembling systemic lupus erythematosis in human
(4). These mice also suffer from a large accumulation of non-
malignant CD4~CD8~ T cells in the spleen and in lymph
nodes. Genetic analysis indicated that the gld phenotype
results from a mutation in FasL (5,6). The Ipr mutation has
been correlated with a defect in Fas (7).
The Fas system unquestionably plays a crucial role in the
deletion of autoimmune cells. Fas-mediated elimination occurs
in the periphery, since both negative and positive selection
in the thymus proceed normally in gld (or Ipr) animals (8,9).
Fas also plays an important role in T cell cytotoxicity.
Cytolytic T cells use two major cytolytic pathways, one based
on perforin-granzymes and one dependent on FasL (10-13).
Cytotoxic T cells derived from perforin knock-out mice have
considerable killing activity left (14) which is attributable to
Fas (10-12). In turn, perforin-containing gld cytotoxic T cells
still kill tumor cells, but with reduced efficiency (10).
FasL in gld/gld mice displays no killing activity upon
stimulation with phorbol ester (PMA) and calcium ionophore
(ionomycin) (5,6), in spite of normal mRNA levels present
(5,6), Moreover, activated gld T cells fail to interact with a
FasR.Fc hybrid protein (6,15). This functional loss is a result
of a single point mutation changing Phe273 to Leu proximal
to the extracellular C-terminus of this type II membrane
protein (5,6). In the present study we report on the structural
implications of this fatal single amino acid replacement.
Methods
Expression of bacterial recombinant FasL
cDNA coding for the extracellular domain of FasL was ampli-
fied from 1 ng mouse FasL cDNA (GenBank accession no.
MMU10984) using the following primers: primer 1, 5'-TTC
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GCT CGA GAA CTG GCA GAA CTC CGT GAG-3'; primer 2,
5'-AAG GAT CCT AGC TGA CCT GTT GGA CCT TGC-3'.
The amplified product was cloned into the pCRII vector using
the AT cloning kit (Invitrogen, Heidelberg, Germany) and
subsequently subcloned into the page-KG expression vector
(kindly provided by Dr A. Quest at our institute) at the EcoRI
site. The glutathione-S-transferase (GST)-FasL fusion protein
was expressed in bacteria upon induction with IPTG.
Antibody production
A peptide spanning amino acids 196-220 of the mouse Fas
ligand (RGQSCNNQPLNHKVYMRNSKYPEDL), synthesized
using the multiple antigen technology (16), was used as
antigen. Spleen cells of an immunized rat were fused to NF1
mouse myeloma cells and hybridoma cells secreting peptide
specific IgG were selected. Two clones, H11 and A11, were
further analyzed. The same peptide construct was also
injected into rabbits for polyclonal antibody production. The
antiserum (PE62) was affinity purified on FasL peptide coupled
to CNBr-Sepharose (Pharmacia, Zurich, Switzerland).
Splenocytes and their activation
B6.gld mice were purchased from Jackson Laboratories (Bar
Harbor, ME). Splenocytes were isolated from 6-week-old mice
and freed from red blood cells by 10 min incubation in an ice
cold buffer containing 13 mM sodium bicarbonate, 156 mM
ammonium chloride and 127 |iM EDTA, and then resuspended
in complete medium. Cells were cultured for 4 h at ~1x107
cells/ml in either the presence or the absence of PMA (5 ng/
ml) and ionomycin (500 ng/ml) (Sigma, Buchs, Switzerland).
Flow cytometry
Analysis was performed on a FACScan cytometer (Becton
Dickinson, Mountain View, CA) using the Lysys II software
Cells were stained with the anti-FasL antibody PE62 followed
by donkey anti-rabbit coupled to fluorescein (Dianova,
Hamburg, Germany) and the PE-labeled mAb H 129.19 for
L3T3/CD4 and 53-6.7 for Ly-2/CD8 staining (Boehringer,
Mannheim, Germany).
SDS-PAGE, Western blot and native electrophoresis
Splenocytes were washed in ice cold PBS and then boiled in
sample buffer for 5 min. Cellular proteins of -2x10 6 spleno-
cytes per lane were electrophoretically separated on a 10%
polyacrylamide gel in the presence of SDS under non-
reducing conditions (17) and subsequently transferred to
nitrocellulose. Immunoblot analysis was conducted using
plain supernatant of the mAb H11 and A11, and 50 (ig/ml of
affinity-purified PE62 antibody. First antibodies were detected
using anti-peroxidase-conjugated donkey anti-rat and anti-
rabbit antibodies (Dianova, Hamburg, Germany) followed
by a chemiluminescence reaction using the ECL system
(Amersham, Bucks, UK).
For native electrophoresis the Phast separation system of
Pharmacia (Zurich, Switzerland) was employed. Approxi-
mately 107 splenocytes were lysed in 50 ^J lysis buffer (100
mM NaCI, 1% NP-40 in 50 mM Tris, pH 8.0) containing 1 mM
PMSF. Cell lysate (1 \i\) was applied per lane and the proteins
were electrophoretically separated on 4-15% gradient gels
and analyzed by immunoblot analysis as described above.
Complement C8 and C9 components were used as molecular
weight standards.
Results
Production of FasL specific antibodies
Polyclonal and monoclonal antibodies were generated against
a peptide corresponding to residues 196-220 of the mouse
FasL, predicted to lay on the loop forming the outer tip of
the ligand (see below). Affinity-purified polyclonal antiserum
(PE62) and two independent mAb (H11 and A11) were used
throughout this study. To confirm that these anti-peptide
antibodies specifically recognize FasL, the reactivity of the
antibodies was tested against the recombinant extracellular
domain of FasL. As shown in Fig. 1, both the monoclonal and
polyclonal antibodies recognized bacterial lysates containing
the GST-FasL fusion protein in Western blots, whereas no
band was detectable in lysates transfected with the expression
vector containing FasL insert in the inverse orientation. Flow
cytometric analysis showed reactivity of the polyclonal anti-
body PE62 with the native ligand on the cell surface (Fig. 2),
while the use of the mAb was restricted to the analysis of
denatured protein in Western blots .
Expression of FasL in T lymphocytes of wild-type and gld
mutant mice
FasL mRNA has been detected in activated splenocytes (3,6).
Flow cytometric analysis of activated T lymphocytes derived
from spleens indeed showed high expression of FasL (Fig.
2). The CD4+ and the CD8+ subsets showed equally intense
FasL staining (data not shown). FasL expression was critically
dependent on lymphocyte activation. Only cells that had been
previously treated with PMA/ionomycin were positive, while
marginal staining of T lymphocytes was observed with non-
activated T cells. Interestingly, only a subpopulation of activ-
ated T lymphocytes was FasL positive. Approximately 70%
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Fig. 1. Characterization of anti-mouse FasL antibodies. Western blot
analysis of a bacterial lysate containing recombinant mouse FasL-
GST fusion protein (46 kDa) using the affinity-purified PE62 rabbit
polyclonal antibody to FasL or rat monoclonal anti-mFasL H11. The
low molecular weight bands most likely correspond to degradation
products. Bacterial lysate expressing GST alone served as a negative
control. The D6 mAb antibody detects the peptide 62 in ELISA, but
does not react with the recombinant FasL (control lanes).
remained FasL low. We are currently investigating the pheno-
type of the FasL positive lymphocyte subpopulation in
greater detail.
The relative surface expression of FasL on splenic lympho-
cytes isolated from wild-type B6 mice with that from gid B6
mice was compared Previously, Ramsdell (15) showed that
the FasR.Fc hybrid protein detected the ligand only on wild-
type lymphocytes, whereas the gid T lymphocytes were
negative. Using FasL specific antibodies, however, staining
on PMA/ionomycin treated gldl lymphocytes was comparable
to that of wild-type T lymphocytes (Fig. 2). Only 30% of
activated gid T lymphocytes expressed high levels of FasL.
This was confirmed by Western blot analysis An equal
quantity of protein and an identical size was found in extracts
from activated T lymphocytes of wild-type and of gid origin
(Fig. 3). FasL exhibited a molecular weight of -40 kDa, in
agreement with the molecular weight of post-translationally
modified FasL in transfected COS cells (18).
Structure of the gld-FasL
The inability of the FasR.Fc hybrid protein to detect gld-FasL
points to structural dissimilarities in the Fas binding region of
the ligand. Other members of the TNF family have been
shown to be active only as trimers and not as monomers
(19,20). Similarly, FasL, although present on the surface,
could show impaired dimer or trimer formation on the surface
of gid T cells. This would be compatible with the observed
unstimulated +PMA/lonomycln
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Fig. 2. Expression of FasL on wild-type and gid lymphocytes. FACS
analysis of cell surface FasL expression on unstimulated (left panels)
and PMA/lonomycin (4 h) stimulated (right panels) CD4+ or CD8+
splenocytes of C57BU6J (B6) (A) or B6-gld origin (B). The flow
cytometric profiles show the combined staining of CD4+ and CD8+
splenocytes stained with the anti-FasL polyclonal antibody PE62.
Unrelated antibody control is identical with the profiles of unstimulated
splenocytes (upper left panel).
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difference of FasL surface expression, which differs
depending on whether a FasL antibody or the FasR.Fc hybrid
protein is used as tool for detection. Whereas the antibody
most likely detects multimers and monomers, the receptor.Fc
hybrids are known to interact only with multimeric ligands
with high affinity.
This hypothesis was supported by the spatial localization of
FasL Phe273 to Leu mutation. Although the level of sequence
identity between the individual members of the TNF super-
family does not exceed 35%, their three-dimensional struc-
tures are expected to be very similar as observed for TNF-a
and -p for which X-ray structures are available. Both factors
crystallize in the trimeric form and are detected as such in
solution (20-22). Knowledge-based protein modeling of FasL
was therefore performed (23). Figure 4(A and B) shows the
predicted three-dimensional structure of the presumptive
FasL trimer. The trimer interface is largely dominated by
hydrophobic residues which are well conserved throughout
the TNF family (23). In the gid mutation the bulky aromatic
side chain of Phe273, which is part of the subunit interface,
is replaced by the shorter leucine (Fig. 5A). Phe273 is posi-
tioned at the center of a 12 A sphere where several of the
best conserved residues of the TNF family are clustered
(V144, A145, H146, L158, W160, Y190, V193, G244, A245,
F247, F273, G274), although they are quite distant in the
sequence. This suggests an important functional role for this
particular region. Based on our model of murine FasL, Phe273
(located on strand H) interacts mainly with Ala245 (on strand
F) of the adjacent subunit (Figs 4 and 5). It is responsible for
-50 A2 of the hydrophobic contact surface between individual
protomers. The gld-FasL model predicts that the contribution
of amino acid 273 is reduced by >20 A2 when replaced by a
leucine. This would in turn result in a decrease of hydrophobic
interactions between the subunits and suggest that either
trimer formation of FasL itself is impaired or that local distor-
tions of the polypeptide backbone occur in the gid mutation.
As in the gid mutation, this position is occupied by shorter
hydrophobic residues, i.e. isoleucine and valine, in human
and mouse CD30L respectively (Fig. 5A and B). The molecular
model of the CD30L (23) shows that the consequent difference
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Fig. 3. FasL in splenocytes. Western blot analysis of PMA/ionomycin
(4 h) stimulated wild-type and gid splenocytes. FasL-detecting
antibodies were H11 and A11. No staining is seen with an irrelevant
mAb (data not shown).
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in subunit contact surface is, however, compensated by
CD30LLeu199 which corresponds to FasL:Ala245 (Fig. 5B).
Oligomerization of FasL
To determine if there is a failure of trimerization of the gld-
FasL, Western blot analysis was performed with the native
FasL-recognizing polyclonal PE62 antibody. This antibody
normally detected at least three bands under non-reducing
conditions, the lowest of 40 kDa co-migrating with that
detected by the mAb (Fig. 6A). The two larger bands had
apparent molecular weights of -75 and 105 kDa respectively.
Their molecular masses correlate with the predicted mass of
FasL dimers and trimers, and most likely reflect non-dissoci-
ated oligomeric forms of the ligand.
To obtain additional information with respect to the aggrega-
tion state of FasL in the presence of non-denaturing deter-
gents, activated splenocytes were disrupted with the mild
detergent NP-40. The detergent extract was separated by
native gradient gel electrophoresis. Subsequent immunoblot
analysis revealed multiple FasL-antibody reactive bands. The
lowest one had an apparent molecular size of -200 kDa, but
two additional FasL antibody-reactive species with apparent
molecular masses of -400 and 600 kDa were detected. These
absolute values have to be interpreted with caution, since
NP-40 forms large micellar structures. However, they corres-
pond to dimeric and trimeric forms of the ligand. Importantly,
the pattern of these bands was similar in PMA/ionomycin
activated splenocytes of wild-type and gld origin.
Fig. 4. Molecular model of the murine FasL. Ribbons representation of the murine FasL. In the top view (A), all three subunits, their disulfide
bonds and Phe273 mutated in gld-fasL are represented, while in the side view (B) only the subunits A and C are shown for clarity. The
receptor-binding loops are depicted in blue (darker blue for the loop linking the G and H strands) while the sequence corresponding to
peptide 62 is colored in pink. The green sphere represents the side chain of Ala245 (see Fig. 5A), which is in contact with Phe273 (orange
side chain). The residues at the beginning and end of the receptor-binding GH loop are indicated with light yellow and red circles. The N-
and C-terminal ends of the extracellular FasL sequence which displays homology to the TNF molecule are indicated with white letters, and
the p-strands are identified by black letters on the C subunit.
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Fig. 5. The interface of the g/d-FasL trimer. (A) Multiple amino acid
sequence alignment of TNF superfamily members that are most
similar to FasL (>22% overall identity), i.e. TNF-f), lymphotoxin-p
(LTp) and CD30L. Only the C-terminal region of FasL is shown.
Residues identical in 50% of the sequences are indicated with a
shaded background, while those involved in interface formation in
the gld mutation are labeled in bold face and by arrows. The (}-
strands are indicated in italics. (B) Representation of a section of the
interface between the A (green) and C (blue) subunits of (A) moose
FasL, (B) mouse gld-FasL and (C) human CD30L. The side chains
of FasL:Phe273 and FasL.AIa245 are shown in orange and white
respectively. The corresponding residues of murine CD30L are shown
in the lower panel. The space left empty by the replacement of Phe
by Ile228 in CD30L is filled by the compensatory replacement of Ala
by Leu199. In gld-FasL, the mutation of Phe273 to Leu is not
compensated by the replacement of Ala244 by a larger hydrophobic
residue, leaving a large empty space in the structure. To fHI this
cavity in the trimer structure, gld-FasL may undergo a distortion with
dramatic effect on its FasR-binding activity.
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Fig. 6. Ohgomer formation by FasL. (A) Western blot analysis of PMA/
lonomycin activated splenocytes using the polyclonal affinity-purified
PE62 antibody In the control lanes (con), the first antibody (PE62)
was left out during the incubations Negative results were also
obtained with irrelevant rabbit IgG. (B) Separation of splenocyte
proteins by native gel electrophoresis. FasL antigen was detected
by Western blot analysis using the PE62 antibody.
Discussion
Our results show that the single amino acid change in the
gld mutant FasL allows correct post-translational modification
and sorting of the ligand to the cellular surface. Furthermore,
both the gld- and wild-type FasL seem to form SDS-resistant
oligomers. As shown for soluble members of this ligand family
(24), the membrane-associated form of FasL may require
surface dimerization or trimerization to display functional
activity. There are antibodies to Fas which have ligand-like
activities and induce apoptosis in Fas-bearing cells. The two
original antibodies which have led to the discovery of Fas
(Apo-1) are aggregating antibodies, i.e. of either the IgM or
lgG3 subtype (25,26). F(ab')2 fragments alone are inactive
(27). Thus, it is very likely that FasL homotrimer formation is
required to induce Fas aggregation and signal transduction.
In the context that the apparent aggregation state of the
gld- and wild-type FasL does not differ in vitro, we favor the
conclusion that the g/d-FasL's inability to interact with soluble
Fas dimers (FasR.Fc) and to transmit the signal via Fas results
from a local distortion in FasL-FasR interaction site. Closer
examination of the structure shown in Fig. 4(A) shows that
the critical Phe273 is part of a loop involved in FasR contact
(23). This loop links the strands G and H (the GH loop) and
ends only four residues before Ftie273. The replacement of
Phe273 by a leucine most likely aiters the structure of strand
H in the FasL trimer. It may then be that the modified structure
of strand H changes the conformation of the GH loop giving
rise to a FasL with impaired FasR-binding activity.
Several mutations in the TNF family leading to distinct
phenotypes have been reported. CD40L mutants were dis-
covered in connection with the X-linked hyper-IgM syndrome
(28). The spatial mapping of human CD40L mutants dis-
covered in connection with the X-linked hyper-IgM syndrome
(summarized in 28) show that several of the reported point
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mutations probably affect the folding of individual subunits or
the interaction with the receptor (23). Two mutations, however,
A123—>E and G227->V, are also found at the subunit interface.
Interestingly, these two amino acids are located in the same
three dimensional region as FasL:Phe273 (12 A sphere around
Phe273) and correspond to two of the highly conserved
residues throughout the TNF family Although more polar
subunit interactions (CD40L:Ser256 instead of FasL:Phe273)
replace the very hydrophobic ones in the other members of
the TNF family, mutations in this region of CD40L lead to
ligands with impaired receptor-binding function as evidenced
by the appearance of the X-linked hyper-IgM syndrome in
patients bearing such mutations (28). These mutations may
lead to similar effects on the conformation of the GH loop
(one of the receptor-binding loops) as in FasL and thus
explain the lack of functionality of these mutants. In contrast
to CD40L, no mutation affecting FasL activity has been
described in humans to date. The pathological consequences
of such a mutation, as seen in the gld mouse, may be too
profound to allow its occurrence.
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